DNX Corporation said it has successfully developed and bredgenetically engineered swine that express approximately 25percent authentic human hemoglobin. According to a companystatement, this represents a 150 percent increase overpreviously achieved levels.
DNX (NASDAQ:DNXX), based in Princeton, N.J., has been workingto produce new lines of transgenic pigs expressing greater than20 percent human hemoglobin to total swine hemoglobin. RThislevel of expression, 32 grams/per liter of blood, establishes thefeasibility of using genetically engineered swine to producelarge volumes of human pharmaceuticals proteins, such ashemoglobin, in a cost effecitve manner,S said DNX president andchief executive officer Paul J. Schmitt.
(c) 1997 American Health Consultants. All rights reserved.